PROF. FRANCESCO COGNETTI REGINA ELENA NATIONAL CANCER INSTITUTE, ROME
TAXANES, GEMCITABINE AND MONOCLONAL ANTIBODIES ANTI-HER-2 AND THEIR COMBINED USE: WHAT IS THE BENEFIT IN TERMS OF RESPONSE QUALITY AND SURVIVAL?. PROF. FRANCESCO COGNETTI REGINA ELENA NATIONAL CANCER INSTITUTE, ROME. Rome, 16-18 December 2004. INTRODUCTION.
640 views • 46 slides